93156-92-4

Basic information

• Product Name: Benzoic acid, 3,5-bis(1,1-dimethylethyl)-4-methoxy-
• CAS NO: 93156-92-4
• Molecular Formula: C16H24O3
• Molecular Weight: 264.365
• Mol File: 93156-92-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3,5-bis(1,1-dimethylethyl)-4-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3,5-bis(1,1-dimethylethyl)-4-methoxy-(93156-92-4)
• EPA Substance Registry System: Benzoic acid, 3,5-bis(1,1-dimethylethyl)-4-methoxy-(93156-92-4)

Safety Data

• Hazardous Substances Data: 93156-92-4(Hazardous Substances Data)

Upstream product

• 1518-53-2 1,3-di-tert-butyl-2-methoxy-5-methylbenzene 
• 115126-97-1 methyl 3,5-di-t-butyl-4-methoxybenzoate 
• 1421-49-4 3,5-Di-tert-butyl-4-hydroxybenzoic acid 
• 74-88-4 methyl iodide 

Relevant articles and documents

Design and synthesis of photodissociable ligands based on azoimidazoles for light-driven coordination-induced spin state switching in homogeneous solution

Light-switchable azoimidazoles were rationally designed and synthesized, and their performance was investigated as photodissociable ligands (PDL) and for spin state switching of Ni porphyrins. The rationally designed ligands exhibit a high photochemical conversion rate (trans a? cis > 98%) and no measurable fatigue over a large number of switching cycles at room temperature under air. As compared to the known phenylazopyridines, the phenylazoimidazoles exhibit a much stronger affinity as axial ligands to Ni porphyrin in the binding trans configuration and a low affinity in their cis form. This affinity switching was used to control the coordination number of Ni2+. Concomitant with the change in coordination number is the change of the spin state from triplet (high spin) to singlet state (low spin). We report on phenylazoimidazole-based PDLs that switch the paramagnetic ratio of the investigated nickel species by up to 70%. Consequently, azoimidazoles exhibit considerably higher switching efficiencies than previously described pyridine-based PDLs.

CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds of substituted or unsubstituted cyclylamine derivatives as shown in formulas (1).

Calcium channel inhibitors comprising benzhydril spaced from piperazine

Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.